PriceTargets.com logo

Belite Bio - BLTE Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $218.73
  • Forecasted Upside: 28.67%
  • Number of Analysts: 11
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$169.99 As of 09/15/2026 11:50 AM ET
▼ -3.012 (-1.74%)

This chart shows the closing price for BLTE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Belite Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BLTE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BLTE

Analyst Price Target is $218.73
▲ +28.67% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Belite Bio in the last 3 months. The average price target is $218.73, with a high forecast of $303.00 and a low forecast of $132.00. The average price target represents a 28.67% upside from the last price of $169.99.

This chart shows the closing price for BLTE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 11 investment analysts is to moderate buy stock in Belite Bio. This rating has held steady since November 2025, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/24/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/22/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/20/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/19/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/19/2026
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
6/17/2026
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
8/16/2026
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
9/15/2026

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/9/2026MizuhoBoost TargetOutperform ➝ Outperform$220.00 ➝ $234.00
9/9/2026Jefferies Financial GroupReiterated RatingHold ➝ Hold
9/8/2026HC WainwrightSet Target$245.00
9/4/2026Canaccord Genuity GroupInitiated CoverageBuy$303.00
9/4/2026Canaccord Genuity GroupInitiated CoverageBuy$303.00
9/3/2026UBS GroupReiterated RatingBuy ➝ Buy
9/3/2026HC WainwrightBoost TargetBuy ➝ Buy$214.00 ➝ $245.00
8/18/2026Zacks ResearchDowngradeStrong-Buy ➝ Hold
8/14/2026Morgan StanleyBoost TargetOverweight ➝ Overweight$201.00 ➝ $206.00
8/14/2026BenchmarkReiterated RatingBuy ➝ Buy
8/14/2026MizuhoSet Target$220.00
8/12/2026Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$266.00 ➝ $270.00
8/12/2026HC WainwrightBoost TargetBuy ➝ Buy$200.00 ➝ $214.00
7/22/2026HC WainwrightReiterated RatingBuy ➝ Buy
7/20/2026Zacks ResearchUpgradeHold ➝ Strong-Buy
7/6/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
6/15/2026HC WainwrightReiterated RatingBuy ➝ Buy$200.00
5/26/2026MizuhoLower TargetOutperform ➝ Outperform$223.00 ➝ $215.00
5/22/2026Truist FinancialSet Target$217.00
5/22/2026BenchmarkReiterated RatingBuy ➝ Buy
5/21/2026HC WainwrightReiterated RatingBuy ➝ Buy$200.00
4/22/2026HC WainwrightReiterated RatingBuy ➝ Buy$200.00
4/13/2026HC WainwrightReiterated RatingBuy ➝ Buy$200.00
4/7/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
3/3/2026Needham & Company LLCSet Target$217.00
3/3/2026BenchmarkReiterated RatingBuy ➝ Buy
3/3/2026HC WainwrightBoost TargetBuy ➝ Buy$185.00 ➝ $200.00
3/3/2026Morgan StanleyBoost TargetOverweight ➝ Overweight$191.00 ➝ $201.00
3/3/2026Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$200.00 ➝ $266.00
2/19/2026MizuhoSet Target$223.00
1/28/2026HC WainwrightReiterated RatingBuy ➝ Buy$185.00
1/26/2026Bank of AmericaInitiated CoverageBuy$195.00
1/6/2026Morgan StanleyInitiated CoverageOverweight$191.00
12/3/2025BTIG ResearchSet Target$187.00
12/3/2025BenchmarkReiterated RatingBuy ➝ Buy
12/2/2025Maxim GroupSet Target$200.00
12/2/2025MizuhoSet TargetNeutral ➝ Outperform$105.00 ➝ $194.00
12/2/2025MizuhoUpgradeNeutral ➝ Outperform$105.00 ➝ $194.00
12/1/2025HC WainwrightBoost TargetBuy ➝ Buy$98.00 ➝ $185.00
11/24/2025Cantor FitzgeraldInitiated CoverageOverweight$154.00
11/20/2025MizuhoInitiated CoverageNeutral$105.00
10/31/2025BenchmarkBoost TargetBuy ➝ Buy$80.00 ➝ $132.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/16/2025Zacks ResearchUpgradeStrong Sell ➝ Hold
9/15/2025HC WainwrightLower TargetBuy ➝ Buy$100.00 ➝ $98.00
7/3/2025HC WainwrightReiterated RatingBuy ➝ Buy$100.00
5/15/2025Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight
5/15/2025HC WainwrightReiterated RatingBuy ➝ Buy$100.00 ➝ $100.00
3/26/2025BenchmarkReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
3/18/2025Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight
3/18/2025HC WainwrightReiterated RatingBuy ➝ Buy$100.00 ➝ $100.00
1/21/2025BenchmarkBoost TargetBuy ➝ Buy$57.00 ➝ $79.00
11/15/2024Maxim GroupBoost TargetBuy ➝ Buy$60.00 ➝ $110.00
11/13/2024HC WainwrightBoost TargetBuy ➝ Buy$60.00 ➝ $100.00
9/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
8/13/2024HC WainwrightBoost TargetBuy ➝ Buy$59.00 ➝ $60.00
8/13/2024BenchmarkReiterated RatingBuy ➝ Buy$57.00 ➝ $57.00
6/20/2024Cantor FitzgeraldReiterated RatingOverweight
6/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$59.00 ➝ $59.00
5/16/2024BenchmarkReiterated RatingBuy ➝ Buy$57.00
5/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$59.00
5/15/2024Cantor FitzgeraldReiterated RatingOverweight
3/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$59.00
3/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$59.00
12/27/2023HC WainwrightReiterated RatingBuy ➝ Buy$59.00
12/14/2023Maxim GroupInitiated CoverageBuy$60.00
11/15/2023HC WainwrightReiterated RatingBuy ➝ Buy$59.00
11/7/2023BenchmarkReiterated RatingBuy ➝ Buy$57.00
11/6/2023HC WainwrightBoost TargetBuy ➝ Buy$55.00 ➝ $59.00
8/10/2023HC WainwrightReiterated RatingBuy ➝ Buy$55.00
7/28/2023Cantor FitzgeraldInitiated CoverageOverweight$43.00
7/26/2023Leerink PartnersReiterated RatingOutperform$25.00
7/26/2023SVB SecuritiesInitiated CoverageOutperform$25.00
7/25/2023BenchmarkReiterated RatingBuy ➝ Buy$57.00
7/25/2023HC WainwrightReiterated RatingBuy ➝ Buy$55.00
6/5/2023HC WainwrightLower Target$58.00 ➝ $55.00
4/4/2023HC WainwrightReiterated RatingBuy$58.00
4/4/2023BenchmarkReiterated RatingBuy$57.00
2/21/2023HC WainwrightReiterated RatingBuy$58.00
10/5/2022HC WainwrightReiterated RatingBuy$58.00
8/1/2022HC WainwrightInitiated CoverageBuy$58.00
7/1/2022BenchmarkInitiated CoverageBuy$57.00
(Data available from 9/15/2021 forward)

News Sentiment Rating

0.68 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/17/2026
  • 0 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2026
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/18/2026
  • 3 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/18/2026
  • 1 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/17/2026
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/17/2026
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/16/2026
  • 10 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/15/2026

Current Sentiment

  • 10 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Belite Bio logo
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
Read More

Today's Range

Now: $169.99
Low: $170.00
High: $173.01

50 Day Range

MA: $162.04
Low: $146.68
High: $193.61

52 Week Range

Now: $169.99
Low: $64.80
High: $200.00

Volume

26,834 shs

Average Volume

195,443 shs

Market Capitalization

$6.85 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Belite Bio?

The following Wall Street analysts have issued stock ratings on Belite Bio in the last twelve months: Bank of America Corporation, Benchmark Co., BTIG Research, Canaccord Genuity Group Inc., Cantor Fitzgerald, HC Wainwright, Jefferies Financial Group Inc., Maxim Group, Mizuho, Morgan Stanley, Needham & Company LLC, Truist Financial Corporation, UBS Group AG, Wall Street Zen, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for BLTE.

What is the current price target for Belite Bio?

0 Wall Street analysts have set twelve-month price targets for Belite Bio in the last year. Their average twelve-month price target is $218.73, suggesting a possible upside of 26.4%. Canaccord Genuity Group Inc. has the highest price target set, predicting BLTE will reach $303.00 in the next twelve months. Benchmark Co. has the lowest price target set, forecasting a price of $132.00 for Belite Bio in the next year.
View the latest price targets for BLTE.

What is the current consensus analyst rating for Belite Bio?

Belite Bio currently has 1 sell rating, 2 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for BLTE.

What other companies compete with Belite Bio?

Other companies that are similar to Belite Bio include Zoetis, Viatris, Neurocrine Biosciences, Jazz Pharmaceuticals and Corcept Therapeutics. Learn More about companies similar to Belite Bio.

How do I contact Belite Bio's investor relations team?

The company's listed phone number is 858-246-6240 and its investor relations email address is [email protected]. The official website for Belite Bio is belitebio.com. Learn More about contacing Belite Bio investor relations.